How to buy Eledon Pharmaceuticals stock

Eledon Pharmaceuticals, Inc is a biotechnology business based in the US. Eledon Pharmaceuticals shares (NVUS) are listed on the NASDAQ and all prices are listed in US Dollars. Eledon Pharmaceuticals employs 7 staff and has a market cap (total outstanding shares value) of 0.00.

Eledon Pharmaceuticals share price

Use our graph to track the performance of NVUS stocks over time.

Eledon Pharmaceuticals shares at a glance

• Key figures

Information last updated 2021-03-08.

52-week range	$4.50 - $26.44
50-day moving average	$15.71
200-day moving average	$15.63
Wall St. target price	$35.00
PE ratio	2.0936
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-1.70

Buy Eledon Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Eledon Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Eledon Pharmaceuticals, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Eledon Pharmaceuticals under- or over-valued?

Valuing Eledon Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Eledon Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Eledon Pharmaceuticals's P/E ratio

Eledon Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 2x. In other words, Eledon Pharmaceuticals shares trade at around 2x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Eledon Pharmaceuticals's PEG ratio

Eledon Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.01. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Eledon Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Eledon Pharmaceuticals financials

Gross profit TTM	$0
Return on assets TTM	-7.29%
Return on equity TTM	-21.07%
Profit margin	0%
Book value	$16.87
Market capitalisation	$21 million

TTM: trailing 12 months

Shorting Eledon Pharmaceuticals shares

There are currently 108,935 Eledon Pharmaceuticals shares held short by investors – that's known as Eledon Pharmaceuticals's "short interest". This figure is 7.3% down from 117,523 last month.

There are a few different ways that this level of interest in shorting Eledon Pharmaceuticals shares can be evaluated.

Eledon Pharmaceuticals's "short interest ratio" (SIR)

Eledon Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Eledon Pharmaceuticals shares currently shorted divided by the average quantity of Eledon Pharmaceuticals shares traded daily (recently around 21962.701612903). Eledon Pharmaceuticals's SIR currently stands at 4.96. In other words for every 100,000 Eledon Pharmaceuticals shares traded daily on the market, roughly 4960 shares are currently held short.

However Eledon Pharmaceuticals's short interest can also be evaluated against the total number of Eledon Pharmaceuticals shares, or, against the total number of tradable Eledon Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Eledon Pharmaceuticals's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Eledon Pharmaceuticals shares in existence, roughly 80 shares are currently held short) or 0.1024% of the tradable shares (for every 100,000 tradable Eledon Pharmaceuticals shares, roughly 102 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Eledon Pharmaceuticals.

Find out more about how you can short Eledon Pharmaceuticals stock.

Eledon Pharmaceuticals share dividends

We're not expecting Eledon Pharmaceuticals to pay a dividend over the next 12 months.

Have Eledon Pharmaceuticals's shares ever split?

Eledon Pharmaceuticals's shares were split on a 1:18 basis on 4 October 2020. So if you had owned 18 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Eledon Pharmaceuticals shares – just the quantity. However, indirectly, the new 1700% higher share price could have impacted the market appetite for Eledon Pharmaceuticals shares which in turn could have impacted Eledon Pharmaceuticals's share price.

Eledon Pharmaceuticals share price volatility

Over the last 12 months, Eledon Pharmaceuticals's shares have ranged in value from as little as $4.5 up to $26.44. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Eledon Pharmaceuticals's is 2.3075. This would suggest that Eledon Pharmaceuticals's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Eledon Pharmaceuticals overview

Eledon Pharmaceuticals, Inc. , a specialty pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. The company's lead product is OP0201, a surfactant-based nasal aerosol drug-device combination product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). It also has a foam-based drug delivery technology OP0101 and OP0102 that could be used to deliver drugs into the ear, nose, and sinus cavities. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021.

Frequently asked questions

What percentage of Eledon Pharmaceuticals is owned by insiders or institutions?
Currently 0.174% of Eledon Pharmaceuticals shares are held by insiders and 13.127% by institutions. How many people work for Eledon Pharmaceuticals?
Latest data suggests 7 work at Eledon Pharmaceuticals. When does the fiscal year end for Eledon Pharmaceuticals?
Eledon Pharmaceuticals's fiscal year ends in December. Where is Eledon Pharmaceuticals based?
Eledon Pharmaceuticals's address is: 19900 MacArthur Boulevard, Irvine, CA, United States, 92612 What is Eledon Pharmaceuticals's ISIN number?
Eledon Pharmaceuticals's international securities identification number is: US67011N2045 What is Eledon Pharmaceuticals's CUSIP number?
Eledon Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 67011N105